Entero Therapeutics, Inc. (ENTO) - Dilution Analysis

10-Q filing | 6.7M shares outstanding

8-K filing: GridAI Technologies Corp. entered into a debt settlement agreement to satisfy obligations by paying $800,000 in cash and issuing 71,482 shares of common stock at $3.25 per share. ($0.23M proceeds)

8-K filing: GridAI Technologies Corp. entered into securities purchase agreements to issue common stock and warrants for aggregate gross proceeds of approximately $7.79 million in private placements. ($7.79M proceeds)

10-Q filing | 2.5M shares outstanding

8-K filing: Entero Therapeutics, Inc. entered into a Securities Purchase Agreement with an investor for a private placement of up to $5,000,000 in gross proceeds through Promissory Notes and a common stock purchase warrant, with an initial closing on October 17, 2025, involving a $500,000 note and a warrant to purchase up to 200,000 shares of common stock. ($0.5M proceeds)

8-K filing: The company filed a Certificate of Designation authorizing the creation of Series H Preferred Stock in the amount of 38,801.546 shares, convertible into common stock at a ratio of 1:1,000 subject to adjustments for stock splits and other corporate actions.

S-1/A filing: The selling stockholders named in this prospectus may use this prospectus to offer and resell from time to time up to an aggregate of 4,945,510 shares of our common stock.

S-1 filing: The selling stockholders may offer and resell up to an aggregate of 4,945,510 shares of common stock issuable upon exercise of pre-funded warrants and common warrants.

8-K filing: Stock split 1-for-3 | Outstanding: 4,765,004 → 1,588,334

10-Q filing | 4.8M shares outstanding

S-1/A filing: This S-1/A filing relates to an offering of 12,000,000 shares of common stock or Pre-funded Warrants to purchase an aggregate of 12,000,000 shares of common stock, with an assumed public offering price of $0.50 per share.

S-1/A filing: S-1/A filing for offering of 12,000,000 shares of common stock or Pre-funded Warrants to purchase an aggregate of 12,000,000 shares of common stock.

S-1/A filing: S-1/A filing for offering of 15,228,426 shares of common stock or Pre-funded Warrants to purchase an aggregate of 15,228,426 shares of common stock.

10-Q filing | 4.8M shares outstanding

S-1 filing: This S-1 filing details a proposed offering of common stock or pre-funded warrants to raise $6,000,000, with the primary use of proceeds for marketing, debt repayment, and development of the Adrulipase product candidate.

10-K filing | 4.8M shares outstanding

8-K filing: Entero Therapeutics, Inc. entered into a Rescission Agreement to unwind the merger transactions with ImmunogenX, Inc., including the rescission of 36,830 common shares and 11,777.418 preferred shares issued in the merger.

10-Q filing | 4.6M shares outstanding

10-Q filing | 2.9M shares outstanding

S-3 filing: This prospectus relates to the offer and resale of up to an aggregate of 3,525,348 shares of common stock issuable upon exercise of common warrants issued to selling stockholders in a warrant inducement transaction which closed on July 12, 2024.

8-K filing: Entero Therapeutics, Inc. entered into a warrant exercise inducement offer letter with a holder to exercise Existing Warrants to purchase 1,762,674 shares of the Company's common stock at $1.09 per share, in exchange for new warrants to purchase up to 3,525,348 shares of the Company's common stock; the Company received aggregate gross proceeds of approximately $1.9 million. ($1.9M proceeds)

S-3 filing: This S-3 filing relates to the offer and resale of up to 1,257,625 shares of common stock held by selling stockholders, issuable upon exercise of warrants from private placements.

10-Q filing | 2.0M shares outstanding

8-K filing: First Wave BioPharma, Inc. completed a registered direct offering of 275,000 shares of common stock and pre-funded warrants to purchase up to 91,000 shares, along with common warrants to purchase up to 732,000 shares, with net proceeds of approximately $0.9 million to be used for working capital and general corporate purposes.

10-K filing | 1.6M shares outstanding

8-K filing: First Wave BioPharma, Inc. acquired ImmunogenX, Inc., issuing 36,830 shares of common stock and 11,777.418 shares of Series G Preferred Stock to ImmunogenX stockholders, and issuing 18,475 shares of Common Stock and 595.808 shares of Series G Preferred Stock to Tungsten Partners LLC as partial compensation for financial advisory services.

8-K filing: First Wave BioPharma, Inc. entered into a placement agency agreement and a securities purchase agreement to sell 173,100 shares of common stock and pre-funded warrants to purchase up to 352,525 shares of common stock in a registered direct offering, with concurrent private placement of common warrants to purchase up to 525,625 shares of common stock, at a price of $7.61 per share of common stock and $7.6099 per pre-funded warrant, with net proceeds of approximately $3.6 million. ($4.0M proceeds)

S-3 filing: This S-3 filing is for the registration of 1,762,674 shares of common stock for resale by selling stockholders, issuable upon exercise of common warrants with an exercise price of $5.00 per share, and the company will not receive any proceeds from the sale.

RW filing: First Wave BioPharma, Inc. is withdrawing its Registration Statement on Form S-1 (File No. 333-275316) because the Company has elected not to proceed with the public offering of securities contemplated by the Registration Statement at this time.

8-K filing: First Wave BioPharma, Inc. entered into a warrant exercise inducement offer letter with a Holder to exercise Existing Warrants for 881,337 shares at $5.50 per share, issuing new warrants to purchase up to 1,762,674 shares and receiving aggregate gross proceeds of approximately $4.8 million. ($9.6M proceeds)

S-1/A filing: This is an S-1/A filing for offering up to 1,381,215 shares of common stock, 1,381,215 pre-funded warrants to purchase up to 1,381,215 shares of common stock, and 2,762,430 common warrants to purchase up to 2,762,430 shares of common stock.

S-1/A filing: The company is filing an S-1/A to register an offering of common stock, common warrants, and pre-funded warrants.

8-K filing: Stock split 1-for-20 | Outstanding: 13,463,479 → 674,998

10-Q filing | 13.5M shares outstanding

S-1 filing: The company is offering shares of common stock, common warrants, and pre-funded warrants.

S-3 filing: This S-3 filing relates to the potential issuance of common stock upon exercise of warrants held by Armistice Capital, with a maximum of 11,764,072 shares issuable, subject to a 4.99% beneficial ownership limitation; the company is also addressing Nasdaq compliance issues regarding minimum stockholders' equity and minimum bid price.

8-K filing: First Wave BioPharma, Inc. completed a warrant exercise inducement offer, resulting in the issuance of 5,882,036 shares of common stock upon exercise of existing warrants and the issuance of new warrants to purchase up to 11,764,072 shares, generating gross proceeds of approximately $4.0 million. ($4.0M proceeds)

10-Q filing | 4.2M shares outstanding

8-K filing: First Wave BioPharma, Inc. completed a public offering of 610,000 shares of common stock, pre-funded warrants to purchase 2,675,000 shares, and common warrants to purchase 6,570,000 shares for net proceeds of approximately $1.8 million.

S-1/A filing: The company is offering shares of common stock, common warrants, and pre-funded warrants to purchase common stock.

S-1/A filing: The company is offering shares of common stock, common warrants and pre-funded warrants.

S-1/A filing: This S-1/A filing includes the offering of up to 6,578,947 shares of common stock, common warrants to purchase up to 13,157,894 shares of common stock, and pre-funded warrants to purchase up to 6,578,947 shares of common stock.

S-3 filing: This S-3 filing registers the resale of up to 3,448,664 shares of First Wave BioPharma, Inc. common stock by selling stockholders.

8-K filing: First Wave BioPharma, Inc. entered into warrant exercise inducement offer letters with certain holders to exercise Existing Warrants for 1,724,332 shares at $1.15 per share, issuing new warrants to purchase up to 3,448,664 shares and receiving aggregate gross proceeds of approximately $2.4 million. ($2.4M proceeds)

10-Q filing | 1.5M shares outstanding

S-3 filing: S-3 filing by Armistice Capital Master Fund Ltd. relating to shares of Common Stock. Includes shares of Common Stock which are not being offered pursuant to this prospectus.

10-K filing | 1.0M shares outstanding

8-K filing: First Wave BioPharma, Inc. entered into a Securities Purchase Agreement with a single institutional investor to issue 128,000 shares of common stock, pre-funded warrants to purchase up to 895,018 shares, and common warrants to purchase up to 2,046,036 shares at a purchase price of $3.91 per share, with expected gross proceeds of approximately $4.0 million. ($4.0M proceeds)

8-K filing: Stock split 1-for-7 | Outstanding: 5,804,671 → 995,003

S-3 filing: This S-3 filing relates to the potential issuance of common stock by the company, which could dilute the economic and voting interests of existing stockholders. The company is also facing challenges in maintaining compliance with Nasdaq's continued listing requirements.

8-K filing: First Wave BioPharma, Inc. entered into a Securities Purchase Agreement for a private placement offering of pre-funded warrants and common warrants with a single institutional investor. ($5.0M proceeds)

10-Q filing | 2.3M shares outstanding

8-K filing: First Wave BioPharma, Inc. closed a public offering on October 11, 2022, selling 255,000 shares of common stock, pre-funded warrants to purchase up to 3,183,396 shares, and common warrants to purchase up to 3,438,396 shares, with net proceeds of $5.2 million used for debt payment, working capital, and corporate purposes.

S-1/A filing: The company is offering shares of common stock, pre-funded warrants, and common warrants with H.C. Wainwright & Co., LLC as the placement agent.

S-1/A filing: The company is offering common stock, pre-funded warrants, and common warrants to purchase shares of common stock, with the offering price based on the last reported sale price of the common stock.

S-1 filing: The company is offering shares of common stock and common warrants, as well as pre-funded warrants to certain purchasers, with H.C. Wainwright & Co., LLC acting as the exclusive placement agent.

8-K filing: Stock split 1-for-30 | Outstanding: 21,807,333 → 1

10-Q filing | 21.8M shares outstanding

S-3 filing: This S-3 filing registers 4,120,000 shares of First Wave BioPharma common stock for resale by selling stockholders, including shares issuable upon conversion of preferred stock and exercise of warrants, with the company not selling any securities or receiving proceeds.

8-K filing: First Wave BioPharma entered into a Securities Purchase Agreement to issue Series D and E Preferred Stock convertible into Common Stock, along with warrants, and filed certificates of designation for the preferred stock, while also planning a reverse stock split amendment. ($0.3M proceeds)

10-Q filing | 21.5M shares outstanding

8-K filing: Holders of 81.3% of Series B Convertible Preferred Stock waived their Series B Exchange Right with respect to any Subsequent Financing occurring on or after January 1, 2022 and the Company permanently reduced the exercise price of the Series B Warrants originally issued on July 16, 2020 held by the Consenting Holders to $0.25 per share or, in the case of Consenting Holders who are officers and directors of the Company, $0.3294.

10-K filing | 16.7M shares outstanding

8-K filing: First Wave BioPharma, Inc. entered into a securities purchase agreement to sell 1,650,000 shares of common stock, pre-funded warrants exercisable for up to 4,848,195 shares, and Series C warrants exercisable for up to 6,498,195 shares in a registered direct offering, with an expected closing on March 2, 2022, and also may issue up to 1,482,153 additional shares of common stock may be issued pursuant to the Series B Exchange Right in excess of amounts currently underlying the Series B Preferred Stock and up to 1,807,203 shares of common stock issuable upon exercise of the Warrants. ($2.29M proceeds)

S-3 filing: This is an S-3 filing for shares of common stock offered by the Selling Stockholders.

8-K filing: First Wave BioPharma, Inc. sold 3,682,120 shares of its common stock under the At The Market Agreement for gross proceeds of approximately $10.5 million, less issuance costs of approximately $327,000. ($10.5M proceeds)

8-K filing | Stock split 10-for-1 | Outstanding: 93,261,897 → 9,965,174 | Transactions: Issuance 624025 Common stock $4.0M to Stockholders of First Wave Bio, Inc. | Proceeds: $4.0M

8-K filing: Stock split 1-for-10 | Outstanding: 93,261,897 → 9,300,000

10-Q filing | 93.3M shares outstanding

S-3 filing: This S-3 filing relates to an at-the-market offering of common stock with an aggregate offering price of up to $50,000,000. The company intends to use the net proceeds for general corporate purposes.

10-Q filing | 78.6M shares outstanding

POS AM filing: This POS AM filing registers the resale of common stock including shares issuable upon exercise of warrants and restricted stock.

10-K filing | 31.2M shares outstanding

S-3/A filing: This S-3/A filing relates to the offering and sale of common stock by selling stockholders. The company will not receive any proceeds from the sale of shares but may receive proceeds from the cash exercise of warrants, which would be used for working capital and general corporate purposes.

S-3 filing: This S-3 filing relates to an offering of common stock by selling stockholders, including shares issuable upon exercise of Series B Exchange Warrants. The company will not receive proceeds from the sale of shares by the selling stockholders, except upon cash exercise of the warrants.

S-1 filing: This S-1 filing registers the resale of common stock issuable upon conversion of Series C Preferred Stock and exercise of Investor Warrants sold in a private placement.

10-Q filing | 28.9M shares outstanding

S-3/A filing: This S-3/A filing registers shares of common stock offered by selling stockholders, including shares issuable upon conversion of Series B Preferred Stock and exercise of various warrants.

10-Q filing | 28.5M shares outstanding

S-3 filing: This S-3 filing registers 50,847,320 shares of common stock offered by selling stockholders, issuable upon conversion of preferred stock and exercise of warrants.

10-Q filing | 28.2M shares outstanding

10-K filing | 26.8M shares outstanding

S-3/A filing: The company filed an S-3/A to register for resale up to 11,583,969 shares of common stock, the Conversion Shares, the Warrant Shares and shares of Common Stock issuable upon conversion of the Placement Agent Warrants.

S-3 filing: This is an S-3 filing for a company issuing common stock, convertible notes, and warrants through multiple offerings. It details an equity line purchase agreement with Lincoln Park Capital Fund, a convertible note offering with warrants, and an underwritten public offering.

S-1/A filing: This is an S-1/A filing including information on a July 2019 underwritten public offering, cyber-related fraud, an amendment to the charter and approved reverse stock split, and a December 2019 convertible note offering.